Lupin, one of the top five drug companies in India, is planning to outlicense its new drugs under development to treat psoriasis within six to nine months.
“We are planning elaborate clinical trials to ensure safety and efficacy and will follow an outlicensing model. We now support our drug discovery programmes with our own funds and outlicensing will be a growth model for our drug discovery programmes in the future,” said D B Gupta, chairman, Lupin.
Lupin has a pipeline of four investigational new drugs (IND) under development in the clinical trial stage. The LL 2011, a herbal formulation to treat psoriasis and named as ‘’Desoris,’ is undergoing advanced phase II clinical trials at seven centres in India. The company is also planning to conduct clinical trials of this formulation in the US. Lupin is also developing a plant-based novel molecule to treat psoriasis.
Codenamed as Desoside-P, the compound is undergoing second phase of clinical trials across seven centres. Its lead drug under development, anti-migraine compound Amigra, is in the third phase of clinical trials at eight centres in India.
Moreover, the company has completed the first phase clinical trials for a tuberculosis molecule, ‘Sudoterb (LL3858). The company also has four other drugs in the pre-clinical development phase for diabetes and rheumatoid arthritis. It has no plans to hive off its research and development programmes.
